Mainline Instruments is pleased to announce the appointment of Jeff Landucci as its new Commercial Director of Ophthalmic Therapeutics, effective February 28, 2025. Well known industry veteran, Landucci will join the senior management team and play a key role in driving the company’s ambitious growth initiatives.
As Commercial Director of Ophthalmic Therapeutics Landucci will focus on leading new and diversified projects, helping Mainline Instruments expand into Ophthalmic Therapeutics to build on its success and broaden its market presence. His appointment comes at an exciting time for the business as it enters into a new exclusive partnership with InMode to distribute the innovative Envision platform, a cutting-edge ophthalmic solution for non-surgical dry eye treatments.
Mainline Instruments has seen continued growth in recent years and remains committed to delivering innovative solutions to the optometry and ophthalmic instrument sectors. With Landucci’s experience the company is looking forward to continued expansion into Ophthalmic Therapeutics and success in the coming years.
FURTHER INFORMATION:
Mainline Instruments
T: +44 (0)121 458 6800
E: sales@main-line.co.uk
W: www.main-line.co.uk
